NRG Therapeutics
PrivateLast Round
Series B
Sep 8, 2025
Total Funding Raised
$95.4M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
NRG Therapeutics operates in Healthcare & Life Sciences and is based in Stevenage. Its latest recorded funding round was a Series B round in September 2025.
NRG Therapeutics is a biotechnology company developing disease-modifying, brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) to treat neurodegenerative disorders such as Parkinson's disease and ALS.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NRG Therapeutics Comparables
Compare NRG Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MitoRx Therapeutics | 87% | |
| Lucy Therapeutics | 85% | |
| Morningside | 81% |
For institutional investors. Book with your work email.
NRG Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 8, 2025 | ||||
| Grant | Oct 31, 2024 | ||||
| Grant | Sep 5, 2024 | ||||
| Grant | Feb 22, 2023 | ||||
| Series A | Nov 9, 2022 | ||||
Grant | May 30, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NRG Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Omega Funds | Series B, Series A |
| SV Health Investors | Series B |
| Parkinson's UK | Series A, Seed, Series B |
| M Ventures | Series B |
| British Business Bank | Series B |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors grew 107% MoM, reaching 1.9K.
- Oct 23, 2025
Kathryn Oliver appointed to newly created role.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 23, 2026
NRG Therapeutics Ltd develops NLRX1-mediated inhibitors of the mitochondrial permeability transition pore to restore mitochondrial function in neurodegenerative diseases.
- hiresSep 3, 2026
NRG Therapeutics Ltd appoints Claus Sundgreen as chief medical officer effective Aug 1st '26 in United Kingdom, with responsibility for clinical development strategy, including NRG5051's Phase 1 trial and planning for a Phase 2 ALS trial.
- attends_eventAug 25, 2026
NRG Therapeutics Ltd presents a poster at the ALS Association's ALS Nexus conference on Aug 23rd-26th '26, detailing preclinical and mechanistic data for NRG5051, its orally bioavailable, CNS-penetrant inhibitor of the mitochondrial permeability transition pore.
For institutional investors. Book with your work email.
NRG Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NRG Therapeutics's valuation, stock price, and market status.
Is NRG Therapeutics a public or private company?
NRG Therapeutics is a private company.
What is the current stock price of NRG Therapeutics?
NRG Therapeutics is a private company, so its shares have no public market price. Caplight tracks NRG Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NRG Therapeutics worth (valuation)?
Valuation information for NRG Therapeutics is not publicly available.
Can I buy NRG Therapeutics stock?
NRG Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NRG Therapeutics's last funding round?
NRG Therapeutics's most recent funding round was Series B on September 8, 2025.
Who are the main investors in NRG Therapeutics?
Key investors in NRG Therapeutics include Omega Funds, SV Health Investors.
Will NRG Therapeutics IPO soon?
No public IPO plans have been announced for NRG Therapeutics.
How can I track NRG Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in NRG Therapeutics's shares on secondary markets.